In the year after the procedure, 57 percent of those who had the actual surgery reported the complete elimination of migraine headaches, compared with just 4 percent in the shamsurgery group.
Medtronic argues that a shamsurgery trial for kyphoplasty is not needed because the Lancet trials followed patients for a full year, and that a placebo effect would be unlikely to persist for this long.
In addition, 84 percent of those who had the surgery reported at least a 50 percent reduction in migraine pain compared with just 58 percent in the sham group.